Elsevier

Physica Medica

Volume 60, April 2019, Pages 120-126
Physica Medica

An in silico planning study comparing doses and estimated risk of toxicity in 3D-CRT, IMRT and proton beam therapy of patients with thymic tumours

https://doi.org/10.1016/j.ejmp.2019.03.028Get rights and content

Highlights

  • Dose distributions was compared between SFUD, 3D-CRT and IMRT in pts with thymic tumours.

  • NTCP for different endpoints was calculated and compared between plans.

  • SFUD was associated with significantly lower doses to organs at risk.

  • The risk of toxicity was reduced with SFUD for several endpoints.

Abstract

Purpose

To compare the dose distributions produced in patients (pts) treated for thymic tumours with spot-scanning proton beam therapy (PBT) implemented with single-field uniform dose (SFUD), intensity-modulated radiation therapy (IMRT) and three-dimensional conformal photon-beam based radiotherapy (3D-CRT).

Methods

Twelve pts, treated with 3D-CRT, were included. Alternative IMRT and SFUD plans were constructed. The IMRT plans were created using a setup with beams incident from 5 to 6 different angles. For the SFUD plans, a field-specific planning target volume (PTV) was created for each patient and a clinical target volume (CTV)-based robust optimization was performed. A robustness evaluation was performed for the CTV for all SFUD plans. A dosimetric evaluation was conducted for the doses to the CTV and organs at risk (OARs) for all plans. The normal tissue complication probability (NTCP), for different endpoints, was calculated using the Lyman-Kutcher-Burman (LKB)-model and compared between plans.

Results

SFUD was associated with significantly lower mean doses to the oesophagus, the heart, the left anterior descending coronary artery (LAD), lungs and breasts compared to 3D-CRT and IMRT. The maximum dose given to the spinal cord was significantly lower with SFUD. The risks for pneumonitis, esophagitis and myelopathy were significantly reduced in the SFUD plans.

Conclusions

The present study showed dosimetric advantages of using scanned-beam PBT for the treatment of thymic tumours, as compared to 3D-CRT and IMRT, especially in regard to lower doses to the oesophagus and lungs. The risk of toxicity was reduced with SFUD.

Introduction

Thymic tumours, i.e. thymoma and thymic carcinoma, derive from the epithelial cells of the thymus gland. Thymic tumours may be non-invasive (WHO Type A thymoma) or show loco regional invasive, or even metastatic traits (WHO Type B thymomas and Type C thymic carcinomas, respectively) [1]. Thymectomy is the main, and sometimes definitive, treatment. Patients (pts) with positive surgical margins, gross residual disease, tumour recurrence or unresectable tumours, may be treated with radiotherapy (RT), in a neo-/adjuvant, salvage or definitive setting. Prescribed doses depend on the clinical indication, with lower doses given to pts with minimal or positive surgical margins (45–60 Gy) and higher doses to patients with gross residual disease or unresectable tumours (60–70 Gy) [2]. Radiotherapy is often combined with platinum-based chemotherapy [2].

Due to its location in the anterior mediastinum, the thymus is closely adjacent to several critical organs, such as heart, lungs, oesophagus and spinal cord. Several studies on RT in thoracic tumours, e.g. breast cancer, lymphoma, lung-, and oesophageal cancer, have shown a wide range of acute and long-term toxicities, e.g., pneumonitis, pericarditis, esophagitis, myelitis and cardiovascular events [3], [4], [5], [6]. As the long-term survival for many thymoma pts is excellent, avoidance of severe RT-related side effects is vital.

A small number of studies have shown dosimetric advantages when using proton beam therapy (PBT) in the treatment of thymic tumours as compared to photon RT, especially with regard to doses to the organs at risk (OAR) [7], [8]. In the present study, we evaluate the dosimetric- and NTCP-outcomes for 12 patients treated for thymoma, or thymic carcinoma, comparing spot-scanning PBT implemented with the single-field uniform dose (SFUD) technique and photon beam RT performed with three-dimensional conformal radiotherapy (3D-CRT) and intensity-modulated radiation therapy (IMRT). Multi-field optimization was not used due to uncertainties in the produced dose distributions, caused by possible organ movement, associated with this method.

Section snippets

Material and methods

The Regional Medical Ethics Committee has approved this study.

Dosimetric comparison

For all pts, the robustness criteria set for the CTV and spinal cord were met with the SFUD plans. The planning objective for the PTV (3D-CRT plans) and the constraints for the OARs (3D-CRT and SFUD plans) were also respected. Typical dose distributions obtained with 3D-CRT and SFUD plans are shown in Fig. 1, for a representative patient case. The obtained DVHs for the CTV and the OARs with the 3D-CRT and the SFUD plans are also presented for this patient (Fig. 2).

For the 3D-CRT, IMRT and the

Discussion

In the present study, we demonstrate dosimetric advantages of using SFUD delivered with scanned proton beams in the treatment of thymic tumours, as compared to photon 3D-CRT and IMRT. The probability of observing different toxicities was also evaluated for the three treatment modalities. A good CTV dose-coverage was obtained with both the SFUD plans and the clinically used photon plans. The dose-volume values for several OARs were significantly lower with the SFUD plans, than in the

Conclusion

The present study confirms the dosimetric advantage of using PBT in the treatment of thymic tumours, as compared to 3D-CRT and IMRT, in regard to lower doses to OARs, and in reducing the risk of toxicity, especially to the lung and oesophagus. Randomized, prospective studies, comparing PBT with photon radiotherapy, should be performed to confirm PBT as a feasible alternative in the treatment of thymic tumours.

Acknowledgements

Declarations of interest: None.

Funding: this research did not receive any specific grant from funding agencies in the public, commercial, or not-for profit sectors. Gracinda Mondlane and Albert Siegbahn would like to acknowledge the support of the cancer research funds of Radiumhemmet.

References (45)

  • L.B. Marks et al.

    Use of normal tissue complication probability models in the clinic

    Int J Radiat Oncol Biol Phys

    (2010)
  • P. McGale et al.

    Incidence of heart disease in 35,000 women treated with radiotherapy for breast cancer in Denmark and Sweden

    Radiotherapy Oncol

    (2011)
  • I. Improta et al.

    Bladder spatial-dose descriptors correlate with acute urinary toxicity after radiation therapy for prostate cancer

    Phys Med

    (2016)
  • V. Landoni et al.

    Predicting toxicity in radiotherapy for prostate cancer

    Phys Med

    (2016)
  • F. Palorini et al.

    Bladder dose-surface maps and urinary toxicity: Robustness with respect to motion in assessing local dose effects

    Phys Med

    (2016)
  • N. Figura et al.

    Postoperative proton therapy in the management of stage III thymoma

    J Thoracic Oncol

    (2013)
  • B.S. Hoppe et al.

    Effective dose reduction to cardiac structures using protons compared with 3DCRT and IMRT in mediastinal Hodgkin lymphoma

    Int J Radiat Oncol Biol Phys

    (2012)
  • E. Roelofs et al.

    Results of a multicentric in silico clinical trial (ROCOCO): comparing radiotherapy with photons and protons for non-small cell lung cancer

    J Thoracic Oncol

    (2012)
  • J.Y. Chang et al.

    Significant reduction of normal tissue dose by proton radiotherapy compared with three-dimensional conformal or intensity-modulated radiation therapy in Stage I or Stage III non-small-cell lung cancer

    Int J Radiat Oncol Biol Phys

    (2006)
  • T. Arts et al.

    The impact of treatment accuracy on proton therapy patient selection for oropharyngeal cancer patients

    Radiotherapy Oncol

    (2017)
  • T. Yoshimura et al.

    NTCP modeling analysis of acute hematologic toxicity in whole pelvic radiation therapy for gynecologic malignancies – A dosimetric comparison of IMRT and spot-scanning proton therapy (SSPT)

    Phys Med

    (2016)
  • P.C. Park et al.

    A beam-specific planning target volume (PTV) design for proton therapy to account for setup and range uncertainties

    Int J Radiat Oncol Biol Phys

    (2012)
  • Cited by (0)

    View full text